ASH2019注目テーマ Late-Breaking Abstracts Session #6

再発難治MM治療でのダラツムマブの上乗せで
カルフィルゾミブ＋デキサメタゾン2剤よりPFSが延長 Carfilzomib, Dexamethasone, and Daratumumab versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani（Atrium Health, Charlotte, NC）